Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Antipsychotics have been found to reduce BPD symptoms including aripiprazole (mean daily dose: 15 mg); ziprasidone (mean daily dose: 20 to 80 mg), olanzapine (mean daily dose: 5 to 9 mg, daily dose range 5 to 20 mg), haloperidol (mean daily dose 5 mg, daily dose range 4 to 16 mg), Quetiapine XL (at a daily dose of 150 mg). The empirically use of antipsychotics in patients with BPD are considered as off-label use." assertion.
- cohort label "Adults" assertion.
- association label "Antipsychotics have been found to reduce BPD symptoms including aripiprazole (mean daily dose: 15 mg); ziprasidone (mean daily dose: 20 to 80 mg), olanzapine (mean daily dose: 5 to 9 mg, daily dose range 5 to 20 mg), haloperidol (mean daily dose 5 mg, daily dose range 4 to 16 mg), Quetiapine XL (at a daily dose of 150 mg). The empirically use of antipsychotics in patients with BPD are considered as off-label use." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Of relevance, lisdexamfetamine dimesylate, a psy- chostimulant approved for the treatment of ADHD, has been recently assessed and approved for the treat- ment of moderate to severe binge eating disorder in adults.5,6 In a phase 2 efficacy and safety trial, pa- tients with binge eating disorder who were prescribed doses of 50 and 70 mg/day doses of lisdexamfetamine demonstrated reduced binge eating days per week, greater binge eating cessation rates, and greater rates of clinical global improvement at 11 weeks compared with the placebo control group" assertion.
- association label "Metformin has been approved by the FDA to treat type 2 diabetes mellitus in both adults and children over the age of 10 years but does not have approval for treating obesity in children or adults" assertion.
- cohort label "Children and adolescents" assertion.
- cohort label "Children and adolescents" assertion.
- association label "Citalopram, although unlicensed in this age group, was the most popular SSRI, accounting for around 40% of all new prescriptions, followed by fluoxetine at over one-third" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Awesome step for rotating an image by any angle" assertion.
- angle_rotation label "angle_rotation" assertion.
- association label "A Danish study using a national registry indicated a 4.7-fold increase in prescriptions of atomoxetine, methylphenidate, and dexamphetamine for children with ASD from 2003 to 2010" assertion.
- cohort label "Children" assertion.
- association label "Quetiapine is prescribed off-label for many disorders including the following: • Augmentation in major depressive disorder; • Obsessive–compulsive disorder; • Post-traumatic stress disorder; • Insomnia; • Behavioural disturbance in dementia; • Borderline personality disorder; • Alcohol dependence; • Cannabis withdrawal." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Quetiapine is prescribed off-label for many disorders including the following: • Augmentation in major depressive disorder; • Obsessive–compulsive disorder; • Post-traumatic stress disorder; • Insomnia; • Behavioural disturbance in dementia; • Borderline personality disorder; • Alcohol dependence; • Cannabis withdrawal." assertion.
- cohort label "Adults" assertion.
- association label "Quetiapine is prescribed off-label for many disorders including the following: • Augmentation in major depressive disorder; • Obsessive–compulsive disorder; • Post-traumatic stress disorder; • Insomnia; • Behavioural disturbance in dementia; • Borderline personality disorder; • Alcohol dependence; • Cannabis withdrawal." assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "An awesome function to flip an image from left to right" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- step label "awesome image converter" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "awesome image converter" assertion.
- image label "image" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- image label "image" assertion.
- assertion label "Example" assertion.
- ExampleNanopub label "example nanopublication" assertion.
- ExampleNanopub label "example nanopublication" assertion.
- ExampleNanopub label "example nanopublication" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- step label "Add an awesome Watermark to your image (licence:cc0,author:rsiebes, date:06-05-2021 )" assertion.
- LinguisticSystem label "python" assertion.
- text label "text" assertion.
- ID_AMR label "Infectious Disease and Antimicrobial Resistance Community" assertion.
- association label "Valproate and carbamazepine are commonly used empirically (off-label) for putative long-term mood-stabilizing effects" assertion.
- cohort label "Adults" assertion.
- cohort label "Children" assertion.
- association label "The 2 other medications for which off-label prescriptions were written for children ages 3 to 5-years included dexmethylphenidate, both immediate (20/2233) and extended release (20/2233), and lisdexamfetamine (42/2233)." assertion.
- cohort label "Children" assertion.
- association label "In our study, extended-release dextroamphetamine-containing medications represented 8% (180/2233) of the overall off-label prescribing in children 3 to 5 years old and, as with methylphenidate, larger doses (25–30 mg) of dextroamphetamine were noted." assertion.
- association label "Clonidine and guanfacine (immediate and extended release combined) accounted for 42.6% (952/2233) of the off-label prescriptions written for the 3- to 5-year-old age group." assertion.
- cohort label "Children" assertion.
- association label "cabometyx is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma rcc 1 1 patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib 1 2 cabometyx is indicated for the treatment of patients with advanced renal cell carcinoma rcc cabometyx is indicated for the treatment of patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib" assertion.
- ReferredObject label "the URL of the paper or text this review comment is about" assertion.
- comment label "This comment" assertion.
- reviewComment label "The content of this comment as free text" assertion.
- impact label "integer value from 1 (low impact) to 5 (high impact)" assertion.
- assertion label "Making a review comment according to the LinkFlows model" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- refersTo label "refers to" assertion.
- hasImpact label "has impact level" assertion.
- hasImpact label "has impact level" assertion.
- hasImpact label "has impact level" assertion.
- hasImpact label "has impact level" assertion.
- hasImpact label "has impact level" assertion.
- hasImpact label "has impact level" assertion.